Sign Up to like & get
recommendations!
0
Published in 2021 at "Journal of Clinical Pharmacology"
DOI: 10.1002/jcph.1855
Abstract: PERJETA (pertuzumab), administered with Herceptin (trastuzumab), is used in the treatment of human epidermal growth factor receptor 2‐positive breast cancer. Pertuzumab is currently approved with an initial loading dose of 840 mg, followed by a…
read more here.
Keywords:
impact dose;
pertuzumab;
dosing regimens;
alternative dosing ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2021 at "Thrombosis and haemostasis"
DOI: 10.1055/a-1499-0030
Abstract: BACKGROUND When emicizumab is dosed according to label, clinicians are obligated to discard or overdose medication due to discrepancies between calculated dose and vial content. The aim of this study was to compose a cost-efficient…
read more here.
Keywords:
emicizumab dosing;
cost;
alternative dosing;
cost efficient ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2025 at "Clinical and Translational Science"
DOI: 10.1111/cts.70223
Abstract: Tislelizumab 200 mg once every 3 weeks (Q3W) is approved for the treatment of multiple cancers. We used a model‐based approach to propose three alternative dosing regimens, 150 mg Q2W, 300 mg Q4W, and 400 mg Q6W, with the aims…
read more here.
Keywords:
model based;
based approach;
dosing regimens;
200 q3w ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2025 at "Diabetes"
DOI: 10.1111/dom.16229
Abstract: To discover alternative dosing regimens of incretin mimetics that simultaneously reduce costs and maintain weight loss efficacy. As a secondary objective, we used our results to explore how allocating a limited incretin mimetics budget could…
read more here.
Keywords:
reduce costs;
weight loss;
dosing regimens;
costs maintain ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.16_suppl.e13564
Abstract: e13564 Background: Hospitals contribute significantly to greenhouse gas (GHG) emissions and face a moral obligation to prioritize reduction of GHG emissions. Drugs constitute an important component of the GHG emissions of hospitals. Alternative dosing strategies…
read more here.
Keywords:
treatment;
carbon;
ghg emissions;
pembrolizumab nivolumab ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2023 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2023.1109866
Abstract: Ropeginterferon alfa-2b is a novel, long-acting mono-pegylated proline-IFN-alpha-2b approved for treatment of polycythemia vera in adults, regardless of thrombotic risk level or treatment history. Clinical trial data indicate the dose and titration of ropeginterferon alfa-2b…
read more here.
Keywords:
ropeginterferon alfa;
dosing strategy;
alternative dosing;
ropeginterferon ... See more keywords